A large body of evidence supports the hypothesis that CCK is an important element in the neurochemical balance that is thought to be essential for normal nervous system function. Much of the research on the biological actions of CCK have focused on its role in anxiety, cognitive function, analgesia, substance abuse and in the control of feeding. Altered CCK synthesis and/or release could be involved in the pathophysiology or symptomatology of neurological and psychiatric disease. One of the key events in CCK biosynthesis involves the concerted action of specific endoproteolytic enzymes which cleave pro CCK in a strict temporal order to produce CCK 8. The identity of the enzymes responsible for these cleavages in the brain are unknown but some good candidates have been identified in endocrine tumor cells. The experiments detailed in this proposal continue ongoing studies examining the ability of PC 1, PC2, and PC5 alone or in combination to appropriately cleave pro CCK in endocrine cells and extend these investigations to neuronal cells in culture and to transgenic mice in which PC2 has been knocked out by homologous recombination. The short term goal of this research is to understand the mechanism and regulation of the post-translational processing of pro-cholecystokinin (CCK). The long term goal is to understand what role CCK plays in the brain. By understanding the mechanism and regulation of CCK biosynthesis and processing, it may be possible to alter the rate of synthesis and release of CCK to adjust the neurochemical balance in areas like the striatum and provide some relief of symptoms in specific Neurological Diseases such as Parkinson's. This proposal addresses the following specific aims which test the hypothesis that the action of PC 1, PC2 and PC5 either alone or in combination are required to process pro CKK to CCK 8 amide or other biologically active forms in endocrine and neuronal cells: 1. The ability of PC1, PC2 and PC5 to process pro CCK will be studied in endocrine tumor cells, neuroblastoma cells, immortalized hippocampal neurons, neural progenitor cells before and after differentiation. 2. Using purified recombinant pro CCK and synthetic peptides containing specific cleavage sites, the ability of recombinant PC 1,PC2 and PC5 to cleave pro CCK in vitro will be tested. 3. The role of PC2 in pro CCK processing in brain will be extended to intact animals by examining the products of pro CCK processing in PC2 knockout mice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS031602-06S1
Application #
6322937
Study Section
Special Emphasis Panel (ZRG1 (01))
Program Officer
Kitt, Cheryl A
Project Start
1994-05-01
Project End
2002-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
6
Fiscal Year
2000
Total Cost
$50,000
Indirect Cost
Name
Tufts University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Beinfeld, Margery C; Funkelstein, Lydiane; Foulon, Thierry et al. (2009) Cathepsin L plays a major role in cholecystokinin production in mouse brain cortex and in pituitary AtT-20 cells: protease gene knockout and inhibitor studies. Peptides 30:1882-91
Reynolds, Nicole A; Blum, Alissa; Kitagawa, Kouki et al. (2006) Inhibition of PC5 expression decreases CCK secretion and increases PC2 expression. Peptides 27:901-4
Burgdorf, Jeffrey; Panksepp, Jaak; Beinfeld, Margery C et al. (2006) Regional brain cholecystokinin changes as a function of rough-and-tumble play behavior in adolescent rats. Peptides 27:172-7
Beinfeld, Margery C; Vishnuvardhan, Daesety; Blum, Alissa et al. (2006) Inhibition of prohormone convertase 1 (PC1) expression in cholecystokinin (CCK) expressing At-T20 cells decreased cellular content and secretion of CCK and caused a shift in molecular forms of CCK secreted. Peptides 27:905-10
Beinfeld, Margery C; Blum, Alissa; Vishnuvardhan, Daesety et al. (2005) Cholecystokinin levels in prohormone convertase 2 knock-out mouse brain regions reveal a complex phenotype of region-specific alterations. J Biol Chem 280:38410-5
Tagen, Michael B; Beinfeld, Margery C (2005) Recombinant prohormone convertase 1 and 2 cleave purified pro cholecystokinin (CCK) and a synthetic peptide containing CCK 8 Gly Arg Arg and the carboxyl-terminal flanking peptide. Peptides 26:2530-5
Cadel, Sandrine; Gouzy-Darmon, Cecile; Petres, Stephane et al. (2004) Expression and purification of rat recombinant aminopeptidase B secreted from baculovirus-infected insect cells. Protein Expr Purif 36:19-30
Cain, B M; Connolly, K; Blum, A C et al. (2004) Genetic inactivation of prohormone convertase (PC1) causes a reduction in cholecystokinin (CCK) levels in the hippocampus, amygdala, pons and medulla in mouse brain that correlates with the degree of colocalization of PC1 and CCK mRNA in these structures J Neurochem 89:307-13
Kleditzsch, Petra; Pratt, John; Vishnuvardhan, Daesety et al. (2003) Production, purification, and characterization of rat pro-CCK from serum-free adapted Drosophila cells. Protein Expr Purif 31:56-63
Cain, Brian M; Connolly, Kelly; Blum, Alissa et al. (2003) Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1, PC2, and PC5 in rat brain. J Comp Neurol 467:307-25

Showing the most recent 10 out of 30 publications